Comparative kinetics of the uremic toxin p-cresol versus creatinine in rats with and without renal failure

Kidney International

Volumn 64, Issue 4, 2003, Pages 1365-1373

  Lesaffer, Gerrit ^a,b   De Smet, Rita ^a   D'heuvaert, Tommy ^a   Belpaire, Frans M ^a   Lameire, Norbert ^a   Vanholder, Raymond ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Creatinine; Glucuronidation; Kinetics; P cresol; Rats; Volume of distribution

Indexed keywords

4 CRESYLGLUCURONIDE; CREATININE; GLUCURONIDE; PARA CRESOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; HALF LIFE TIME; HYDROLYSIS; KIDNEY CLEARANCE; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; UREMIA; URINARY EXCRETION; XENOBIOTIC METABOLISM;

EID: 0141786856     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00228.x     Document Type: Article

References (51)

1. NIWA T, MAEDA K, OHKI T, SAITO A: A gas chromatographic-mass spectrometric analysis for phenols in uraemic serum. Clin Chim Acta 110:51-57, 1981
2. OGATA N, MATSUSHIMA N, SHIBATA T: Pharmacokinetics of wood creosote: Glucuronic acid and sulfate conjugation of phenolic compounds. Pharmacology 51:195-204, 1995
3. DE SMET R, GLORIEUX G, HSU C, VANHOLDER R: P-cresol and uric acid: Two old uraemic toxins revisited. Kidney Int 52(Suppl 62):S8-S11, 1997
4. DE SMET R, DAVID F, SANDRA P, et al: A sensitive HPLC-method for the quantification of free and total p-cresol in patients with chronic renal failure. Clin Chim Acta 278:1-21, 1998
5. VANHOLDER R, DE SMET R, LESAFFER G: p-Cresol: A toxin revealing many neglected but relevant aspects of uraemic toxicity. Nephrol Dial Transplant 14:2813-2815, 1999
6. VANHOLDER R, DE SMET R: Pathophysiologic effects of uraemic retention solutes. J Am Soc Nephrol 10:1815-1823, 1999
7. LESAFFER G, DE SMET R, LAMEIRE N, et al: Intradialytic removal of protein-bound uraemic toxins: Role of solute characteristics and of dialyzer membrane. Nephrol Dial Transplant 15:50-57, 2000
8. BAKKE OM: Studies on the degradation of tyrosine by rat caecal contents. Scand J Gastroent 4:603-608, 1969
9. BONE E, TAMM A, HILL M: The production of urinary phenols by gut bacteria and their possible role in the causation of large bowel cancer. Am J Clin Nutr 29:1448-1454, 1976
10. CURTIUS HC, METTLER M: Studies of the intestinal tyrosine metabolism using stable isotopes and gas chromatography-mass spectrometry. J Chromatogr 126:569-580, 1976
11. YOKOYAMA MT, TABORI C, MILLER ER, HOGBERG MG: The effects of antibiotics in the weanling pig diet on growth and the excretion of volatile phenolic and aromatic bacterial metabolites. Am J Clin Nutr 35:1417-1424, 1982
12. EVENEPOEL P, CLAUS D, GEYPENS B, et al: Evidence for impaired assimilation and increased colonic fermentation of protein, related to gastric acid suppression therapy. Aliment Pharmacol Ther 12:1011-1019, 1998
13. ABREO K, SELLA M, GAUTREAUX S, et al: p-Cresol, a uraemic compound, enhances the uptake of aluminum in hepatocytes J Am Soc Nephrol 8:935-942, 1997
14. LASCELLES PT, TAYLOR WH: The effect upon tissue respiration in vitro of metabolites which accumulate in uraemic coma. Clin Sci 31:403-413, 1966
15. THOMPSON DC, PERERA K, FISHER R, BRENDEL K: Cresol isomers: Comparison of toxic potency in rat liver slices. Toxicol Appl Pharmacol 125:51-58, 1994
16. VANHOLDER R, DE SMET R, WATERLOOS MA, et al: Mechanisms of uraemic inhibition of phagocyte reactive species production: Characterization of the role of p-cresol. Kidney Int 47:510-517, 1995
17. NIWA T: Organic acids and the uraemic syndrome: Protein metabolite hypothesis in the progression of chronic renal failure. Semin Nephrol 16:167-182, 1996
18. BERGSTRÖM J: Uraemic toxicity, in Nutritional Management and Renal Disease, edited by Kopple JD, Massry SG, Baltimore, Williams & Wilkins, 1997, pp 97-190
19. VANHOLDER R, DE SMET R, HSU C, et al: Uremic toxicity: The middle molecule hypothesis revisited. Semin Nephrol 14(3):205-218, 1994
20. NIWA T, AOYAMA I, TAKAYAMA F, et al: Urinary indoxyl sulfate is a clinical factor that affects the progression of renal failure. Miner Electrolyte Metab 25:118-122, 1999
21. NIWA T: The protein metabolite theory as a mechanism for the progression of renal failure. J Ren Nutr 11(4):181-182, 2001
22. WRATTEN ML, TETTA C, DE SMET R, et al: Uremic ultrafiltrate inhibits platelet-activating factor synthesis. Blood Purif 17:134-141, 1999
23. VANHOLDER R, RINGOIR S: Infectious morbidity and defects of phagocytic function in end-stage renal disease: A review. J Am Soc Nephrol 3:1541-1554, 1993
24. VANHOLDER R, DELL'AQUILA R, JACOBS V, et al: Depressed phagocytosis in hemodialyzed patients: in vivo and in vitro mechanisms. Nephron 63:409-415, 1993
25. VANHOLDER R, ARGILÉS A, BAURMEISTER U, et al: Uremic toxicity: Present state of the art. Int J Artif Organs 24:695-725, 2001
26. DOU L, CERINI C, BRUNET P, et al: p-cresol, a uremic toxin, decreases endothelial cell response to inflammatory cytokines. Kidney Int 62:1999-2009, 2002
27. LESAFFER G, DE SMET R, BELPAIRE FM, et al: Urinary excretion of the uraemic toxin p-cresol by glucuronidation in the rat: Contribution of glucuronidation to its metabolization. Nephrol Dial Transplant 18:1299-1306, 2003
28. LESAFFER G, DE SMET R, D'HEUVAERT T, et al: Kinetics of the protein-bound, lipophilic, uraemic toxin p-cresol in healthy rats. Life Sci 69:2237-2248, 2001
29. HIDA M, AIBA Y, SAWAMURA S, et al: Inhibition of the accumulation of uraemic toxins in the blood and their precursors in the feces after oral administration of Lebenin®, a lactic acid bacteria preparation, to uraemic patients undergoing haemodialysis. Nephron 74:349-355, 1996
30. MAC NAMARA P, LALKA D, GIBALDI M: Endogenous accumulation products and serum protein binding in uremia. J Lab Clin Med 98:730-740, 1981
31. NIWA T: Phenol and p-cresol accumulated in uraemic serum measured by HPLC with fluorescence detection. Clin Chem 39:108-111, 1993
32. COSTIGAN MG, LINDUP WE: Plasma clearance in the rat of a furan dicarboxylic acid which accumulates in uraemia. Kidney Int 49:634-638, 1996
33. FAGUGLI RM, DE SMET R, BUONCRISTIANI U, et al: Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis. Am J Kidney Dis 40(2):339-347, 2002
34. NIWA T, YAZAWA T, ISE M, et al: Inhibitory effect of oral sorbent on accumulation of albumin-bound indoxyl sulfate in serum of experimental uraemic rats. Nephron 57:84-88, 1991
35. NIWA T, MIYAZAKI T, HASHIMOTO N, et al: Suppressed serum and urine levels of indoxyl sulfate by oral sorbent in experimental uraemic rats. Am J Nephrol 12:201-206, 1992
36. NIWA T, MIYAZAKI T, TSUKUSHI S, et al: Accumulation of indoxyl-beta-D-glucuronide in uraemic serum: Suppression of its production by oral sorbent and efficient removal by haemodialysis. Nephron 74:72-78, 1996
37. NIWA T, EMOTO Y, MAEDA K, et al: Oral sorbent suppresses accumulation of albumin-bound indoxyl sulphate in serum of haemodialysis patients. Nephrol Dial Transplant 6:105-109, 1991
38. NIWA T, ISE M, MIYAZAKI T, MAEDA K: Suppressive effect of an oral sorbent on the accumulation of p-cresol in the serum of experimental uraemic rats. Nephron 65:82-87, 1993
39. NIWA T, ASADA H, TSUTSUI S, MIYAZAKI T: Efficient removal of albumin-bound furancarboxylic acid by protein leaking haemodialysis. Am J Nephrol 15:463-467, 1995
40. NIWA T: Organic acids and the uraemic syndrome: Protein metabolite hypothesis in the progression of chronic renal failure. Semin Nephrol 16:167-182, 1996
41. NIWA T, YAZAWA T, KODAMA T, et al: Efficient removal of albumin-bound furancarboxylic acid, an inhibitor of erythropoiesis, by continuous ambulatory peritoneal dialysis. Nephron 56:241-245, 1990
42. LIN JH, ULM EH, DUGGAN DE: Possible mechanisms for reduced plasma clearance of diflunisal in rat experimental renal failure. J Pharmacol Exp Ther 238:978-984, 1986
43. SHEMIN D, BOSTOM AG, SELHUB J: Treatment of hyperhomocysteinemia in end-stage renal disease. Am J Kidney Dis 38(4 Suppl 1):S91-S94, 2001
44. VAN GULDENER C, STEHOUWER CD: Homocysteine-lowering treatments: An overview. Expert Opin Pharmacother 2:1449-1460, 2001
45. MENARD C, LAMIABLE D, VISTELLE R, et al: Induction and inhibition of cicletanine metabolism in cultured hepatocytes and liver microsomes from rats. Fundam Clin Pharmacol 14:509-518, 2000
46. VAN TELLINGEN A, GROOTEMAN MPC, BARTERS PCM, et al: Long-term reduction of plasma homocysteine levels by super-flux dialyzers in hemodialysis patients. Kidney Int 59:342-347, 2001
47. KEMPERMAN FA, SILBERBUSCH J, SLAATS EH, et al: Glomerular filtration rate estimation from plasma creatinine after inhibition of tubular secretion: Relevance of the creatinine assay. Nephrol Dial Transplant 14:1247-1251, 1999
48. TAKAHIRA R, YONEMURA K, YONEKAWA O, et al: Tryptophan glycoconjugate as a novel marker of renal function. Am J Med 110:192-197, 2001
49. DEPNER TA: Suppression of tubular anion transport by an inhibitor of serum protein binding in uraemia. Kidney Int 20:511-518, 1981
50. BULLINGHAM RE, NICHOLLS AJ, KAMM BR: Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34:429-455, 1998
51. HATANAKA T: Clinical pharmacokinetics of pravastatin: Mechanisms of pharmacokinetic events. Clin Pharmacokinet 39:397-412, 2000